This is a routine pipeline update with no new financial data or material events. The key catalysts to watch are IBIO-610 IND filing (2H 2026) and IBIO-600 Phase 1 interim data (1Q 2027). No immediate trading action warranted.
Price Chart
Executive Summary
iBio filed an updated corporate presentation (Ex-99.1) under Items 7.01 and 8.01, highlighting its pipeline of next-generation antibodies for obesity and cardiometabolic diseases. The presentation details preclinical data for IBIO-610 (Activin E antibody), IBIO-600 (myostatin antibody in Phase 1), and IBIO-800 (bispecific antibody for PH-HFpEF), along with near-term catalysts including IBIO-610 IND filing expected in 2H 2026 and IBIO-600 interim Phase 1 data anticipated in 1Q 2027. The filing is a routine update of forward-looking pipeline milestones with no new financial results or material events, making it neutral with low immediate stock impact.
Key Facts
- iBio updated its corporate presentation for investor meetings, filed as Exhibit 99.1.
- Lead programs: IBIO-610 (Activin E antibody), IBIO-600 (myostatin antibody), IBIO-800 (myostatin x Activin A bispecific).
- IBIO-610 IND equivalent filing expected in 2H 2026; Phase 1 initiation expected in 1H 2027.
- IBIO-600 Phase 1 SAD enrollment complete; interim data anticipated in 1Q 2027.
- IBIO-800 IND equivalent filing expected in 1H 2027.
- Cash, cash equivalents and debt securities of $88.0M as of June 30, 2026; cash runway extends into Q4 FY 2028.
- ~64.3M shares outstanding and ~87.3M shares issuable upon exercise of pre-funded warrants as of August 30, 2026.
Financial Impact
No new financial results reported; cash position of $88.0M disclosed as of June 30, 2026.
Risk Factors
- All pipeline programs are preclinical or early-stage clinical with no approved products; regulatory and clinical failure risks are high.
- Significant dilution risk from ~87.3M pre-funded warrants exercisable at $0.001 per share.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001420720-26-000028 |
| Document: ibio-20260914x8k.htm | 0001420720-26-000028 |
| Document: 0001420720-26-000028-index-headers.html | 0001420720-26-000028 |
| Document: 0001420720-26-000028-index.html | 0001420720-26-000028 |
| Document: 0001420720-26-000028.txt | 0001420720-26-000028 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | 8-K | $0.8210 | awaiting T+5 | — | $0.7102 (−13.50%) |
Oct 14, 2026 12d ago | SC 13G | $0.7808 $0.8400 | ▲ +7.58% | ▲ +7.13% | $0.7102 (−9.04%) |
Oct 13, 2026 13d ago | 8-K | $0.7818 $0.8210 | ▲ +5.01% | ▲ +6.17% | $0.7102 (−9.16%) |
Sep 14, 2026 5w ago | 8-K | $1.19 $1.33 | ▲ +11.76% | ▲ +9.64% | $0.7102 (−40.32%) |
Aug 28, 2026 8w ago | 8-K | $1.36 $1.31 | ▼ −3.68% | ▼ −3.79% | $0.7102 (−47.78%) |
Aug 28, 2026 8w ago | Press Release | $1.36 $1.31 | ▼ −3.68% | ▼ −3.79% | $0.7102 (−47.78%) |
Jul 1, 2026 16w ago | 8-K | $1.75 $1.59 | ▼ −9.14% | ▼ −9.40% | $0.7102 (−59.42%) |
May 15, 2026 23w ago | 3 | $1.47 $1.84 | ▲ +25.17% | ▲ +24.21% | $0.7102 (−51.69%) |
May 12, 2026 23w ago | Press Release | $1.55 $1.50 | ▲ +3.23% | ▲ +2.07% | $0.7102 (+54.18%) |
May 8, 2026 24w ago | 8-K | $1.66 $1.42 | ▼ −14.46% | ▼ −14.37% | $0.7102 (−57.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers